ALK-Targeted Therapy for Relapsed Neuroblastoma

GD2 CAR-T Therapy for Relapsed Neuroblastoma.pdf

Download PDF • 1.89MB

Hannah Lim | Writer and Researcher

Ayo Adeniran | Writer and Researcher

Ellen Chidebem-Oba | Writer and Researcher

Abstract

Neuroblastoma is the most common extracranial solid tumor in children and is one of the most challenging pediatric malignancies to treat, particularly in patients with relapsed disease. In this study, topics including the risks and standard care, diagnostic approaches and targeted therapy, limitations, as well as the role of anaplastic lymphoma kinase (ALK) gene mutations in disease development and progression, are reviewed. Information was gathered through a comprehensive review of peer-reviewed literature, medical resources and scientific databases, including Mayo Clinic, National Cancer Institute (NIH), Cleveland Clinic and PubMed Central.

Introduction

Neuroblastoma

                Neuroblastoma is a cancer that arises from the nerve tissue, specifically primitive neural cells called neuroblasts. The term neuroblastoma comes from two root words, “neuro,” which refers to nerves, and “blastoma,” which applies to cancer of immature or embryonic cells. Amongst pediatric cancers, neuroblastoma is the most frequently diagnosed extracranial solid malignancy, accounting for less than 15% of cancer-related fatalities in children. It commonly develops in the adrenal glands; however, it can also arise anywhere along the sympathetic nervous system, including the neck, chest, abdomen, and pelvis. Symptoms vary depending on the location, stage, and size of the tumor; however, common symptoms include swollen lymph nodes, physical weakness, limping, extreme weight loss, lumps found in the abdominal area, sudden fevers, fatigue, and pain. Once the initial tumor has developed, the cancer cells can metastasize to other organs, such as the liver, lymph nodes, skin, bone marrow, and bones. The disease accounts for approximately 6-7% of malignancies in children under the age of 14 and affects young children, with most cases occurring before the age of 5. The median age is 17 months, and it is very rare for the disease to occur after the age of 10. Clinical outcomes for patients differ depending on the patient’s biological characteristics and risk classification. Children with low or immediate risk generally have excellent long-term outcomes with 5-year overall survival (OS) rates approaching 95%. In contrast, children with high-risk neuroblastoma have significantly poorer outcomes, with overall survival (OS) rates below 50%.

Relapsed Neuroblastoma

               Relapsed neuroblastoma occurs when a child’s neuroblastoma returns after a period of remission following initial treatment. Many relapsed cases may result from joint effects of biological and genetic factors, including the survival of treatment-resistant tumor cells. Currently, there is no universally accepted standard treatment; rather, treatment is personalized for each patient depending on the extent of relapse, length of time from prior treatment, and the type of prior treatment received. Although treatment outcomes have improved, >50% of children with high-risk neuroblastoma relapse. Relapse continues to be the greatest challenge to achieving long-term survival. In addition, the combination of widespread, highly aggressive, treatment-resistant disease together with organ dysfunction from previous therapy greatly restricts further treatment options, leaving these vulnerable patients with a poor prognosis. Furthermore, understanding patterns of relapse and the clinical and biological characteristics associated with the disease recurrence are essential for developing more effective treatments. Among genetic alterations in relapsed neuroblastoma, mutations in the anaplastic lymphoma kinase (ALK) gene are common and of particular importance; this emerges as a promising therapeutic target.

Anaplastic lymphoma kinase (ALK)

The anaplastic lymphoma kinase (ALK) gene encodes the protein ALK receptor tyrosine kinase and also plays an important physiological role in the development of the brain. Receptor tyrosine kinase proteins are located on the cell surface, and their function is to send signals through hormones or growth factors into the cell. These signals give directions to the cell about growth, metabolism, and division. The function of the ALK receptor tyrosine kinase is unknown, but current evidence suggests that its function has something to do with controlling the growth of nerve cells. When the ALK gene mutates, it causes continuous signalling, promotes uncontrolled tumor growth, increases resistance to apoptosis, and adds to the disease aggressiveness of neuroblastoma. All reported ALK mutations can be classified into three groups: ligand-independent mutations, ligand-dependent mutations, and kinase-dead mutations. These mutations significantly contribute to the development and progression of neuroblastoma by increasing susceptibility to hereditary neuroblastoma, whereas somatic ALK mutations are identified in approx 6-12% of sporadic cases. Targeting these ALK mutations using inhibitors, including lorlatinib and brigatinib, has shown potential to improve the outcomes of treatments. To address this targeting of ALK mutations in neuroblastoma, this review will thoroughly examine the biology of neuroblastoma and ALK mutations, present current statistics, diagnostic approaches, available treatments, and critically evaluate the effectiveness and limitations of ALK-targeted therapies in improving outcomes for children with relapsed neuroblastoma.

Discussion

Why focus on Anaplastic lymphoma kinase (ALK) gene mutations?

• Approximately 75% of familial neuroblastoma cases are associated with the aberrant activation of the germline ALK signaling pathway, while activating somatic ALK mutations are present in roughly 9% of sporadic cases, as said in the literature. In addition, ALK amplifications may occur alongside MYCN amplifications in a small proportion of tumors. These findings show the importance of ALK as a key molecular driver of neuroblastoma. By expanding our understanding of its biology, we hope to contribute to the development of more effective treatment strategies.

• As discussed in the literature review, early clinical trials of first-generation ALK inhibitors such as crizotinib showed limited efficacy. However, more potent second- and third-generation ALK inhibitors, including ceritinib, lorlatinib, brigatinib, alectinib and repotrectinib, have shown improved therapeutic activity in neuroblastoma with ALK mutations, although they achieve complete responses in only a small number of patients. These results show significant progress whilst emphasizing that further research is needed to optimize these therapies. The continuous development of newer ALK inhibitors demonstrated that targeted therapy remains an evolving field with potential, which spurred our interest in this topic.

• Neuroblastoma has the ability to evade the immune system due to its low immunogenicity, resulting in fewer neoantigens for immune cells to recognize and attack. Choosing this topic provided us with the opportunity to explore how advances in precision medicine and therapeutic approaches may help improve treatment responses.

Methods

An in-depth review of existing literature combined with a systematic search strategy was conducted to identify relevant publications on neuroblastoma, relapsed neuroblastoma, anaplastic lymphoma kinase (ALK) gene mutations, and ALK-targeted therapies. Databases, including PubMed Central and Google Scholar, were used alongside reputable medical resources such as the National Cancer Institute, Mayo Clinic, Cleveland Clinic, the National Library of Medicine, and additional information was obtained from peer-reviewed journals.

The literature search entailed keywords and search phrases including “neuroblastoma”, “relapsed neuroblastoma”, “ALK gene mutations”, “targeted immunotherapy for neuroblastoma” and “ongoing treatments for neuroblastoma.” These search terms were used where appropriate to find studies addressing ALK mutations, their role in neuroblastoma and the effectiveness of the target therapies in children.

Peer-reviewed articles published between 2020 and 2025 were favored to ensure the use of current evidence; however, because several landmark studies on this topic were published before this period, earlier sources were also considered. The chosen evidence was then thoroughly analysed and integrated to properly address the research topic.

Diagnosis Methods

Diagnosis of neuroblastoma begins with a comprehensive physical examination, during which a healthcare provider assesses the child for signs and symptoms of the disease and reviews their medical history. Laboratory tests, including blood and urine analyses, are then performed to detect elevated levels of catecholamines, hormones produced by neuroblastoma cells. Because these hormones are rapidly broken down by the body, clinicians measure their metabolites, such as vanillylmandelic acid (VMA) and homovanillic acid (HVA), which are often present at increased levels in affected patients.

A series of imaging studies is then used to identify the primary tumor and determine the extent of disease. An ultrasound is often the initial imaging test because it is noninvasive and can quickly detect abdominal masses. For example, Image 1 shows a large heterogeneous intra-abdominal mass compressing the left kidney.

(Image 1)

Computed tomography (CT) or magnetic resonance imaging (MRI) is subsequently performed, with the choice depending on the child's symptoms and the suspected location of the tumor. These imaging techniques provide detailed information about the tumor's size, location, relationship to surrounding structures, and stage. They also help detect metastases to the lymph nodes, bones, liver, or skin. Image 2 demonstrates a CT scan of the upper abdomen revealing a large retroperitoneal mass encasing the aorta.

(Image 2)

To evaluate the spread of disease, a metaiodobenzylguanidine (MIBG) scan is commonly performed. During this procedure, a radioactive tracer is injected into a vein, where it is selectively absorbed by most neuroblastoma cells. The emitted radiation allows physicians to visualize both the primary tumor and metastatic sites, making the scan valuable for staging the disease, monitoring treatment response, and detecting recurrence. However, because not all neuroblastomas absorb MIBG, a positron emission tomography (PET) scan may be used as an alternative.

A definitive diagnosis is established through a tumor biopsy, in which a sample of tumor tissue is surgically removed for histopathological examination. Bone marrow biopsy and aspiration are also ways to diagnose, where providers remove bone marrow from a patient, typically from pelvic bones, and run tests. These procedures can also help determine if the tumor has spread to the bone marrow or not. Microscopic analysis confirms the presence of neuroblastoma cells, while molecular and genetic testing identifies abnormalities such as MYCN amplification and ALK mutations. These genetic markers help determine prognosis, classify patients into risk groups, and guide treatment decisions.

Another way of diagnosing neuroblastoma is through urinary excretion of the catecholamine metabolites VMA and HVA. Neuroblastoma cells often produce excess catecholamines, which are broken down into VMA and HVA and excreted in the urine. Rather than collecting urine over 24 hours, healthcare providers typically measure the concentration of these metabolites in a single urine sample and compare the results to the amount of creatinine excreted. Elevated levels of VMA and HVA before treatment strongly support the diagnosis of neuroblastoma, and persistently high levels after treatment may indicate that cancer remains or has recurred. In contrast, serum catecholamine levels are not routinely measured to diagnose neuroblastoma because they are less reliable and generally used only in rare or unusual clinical situations.

Stages of Neuroblastoma

Following the diagnosis of neuroblastoma, healthcare professionals determine the stage of the cancer to evaluate the size of the tumor, whether it involves critical structures such as major nerves or blood vessels, and whether it has spread to other areas of the body. Staging is an essential step in developing an appropriate treatment plan because it provides information about the extent of the disease. Although an older staging system relied on findings obtained during surgery, the current International Neuroblastoma Risk Group Staging System (INRGSS) primarily uses imaging studies. This newer system is especially useful because many children begin treatment with chemotherapy before surgery is performed.

The INRGSS classifies neuroblastoma into four stages: L1, L2, M, and MS. 

Stage L1 describes a localized tumor that remains confined to one area of the body and does not involve nearby structures that would make complete surgical removal difficult. 

Stage L2 also refers to a localized tumor; however, the cancer involves nearby nerves, blood vessels, or other important structures that make complete surgical removal more challenging. 

Stage M indicates metastatic neuroblastoma, meaning the cancer has spread to distant parts of the body, such as the bones, bone marrow, liver, or lymph nodes. 

Stage MS is a unique category that applies only to children younger than 18 months whose cancer has spread specifically to the skin, liver, or bone marrow. Despite this limited spread, children with Stage MS disease often have a more favorable prognosis than those with Stage M neuroblastoma.

Neuroblastoma Risk and Standard Care

While staging describes the location and spread of the cancer, it does not fully predict how aggressively the tumor will behave or how likely it is to respond to treatment. For this reason, healthcare providers also classify neuroblastoma into risk groups, which help estimate the likelihood of disease progression or recurrence after treatment. Patients are categorized as having low-risk, intermediate-risk, or high-risk neuroblastoma based on several clinical and biological factors.

One of the most important factors in determining risk is the stage of the cancer. Children with Stage M neuroblastoma generally have the highest risk of recurrence because the disease has already metastasized. Age at diagnosis is another significant factor, as children younger than 18 months typically have better outcomes than older children. In addition, specialists examine the tumor's histology, or how the cancer cells appear under a microscope. Tumors with unfavorable histology, characterized by abnormal cell appearance and behavior, are associated with a poorer prognosis. Genetic testing is also performed to determine whether the tumor has MYCN gene amplification, meaning there are extra copies of the MYCN gene. MYCN amplification promotes rapid tumor growth and is strongly associated with aggressive disease and an increased risk of relapse.

Based on these factors, neuroblastoma is assigned to one of three risk groups:

Low-risk neuroblastoma has a low likelihood of recurrence and can often be successfully treated with surgery alone. In some infants with small adrenal tumors, careful observation without immediate treatment may be appropriate because the tumor can regress spontaneously. 

Intermediate-risk neuroblastoma requires more intensive treatment, typically including chemotherapy to shrink the tumor before surgery, increasing the likelihood of complete removal and reducing the chance of recurrence. 

High-risk neuroblastoma has the greatest probability of relapse and requires aggressive, multimodal treatment. This typically includes intensive chemotherapy, surgical tumor removal, high-dose chemotherapy followed by stem cell (bone marrow) transplantation, radiation therapy, immunotherapy, and, in some cases, targeted therapies or other medications. These combined treatment approaches aim to improve survival while reducing the risk of the cancer returning.

Stage 4S neuroblastoma occurs in children less than 12 months of age with a localized primary tumor and metastases confined to the liver, skin, and/or bone marrow. Categorized by MYCN gene amplification, diploid chromosome status, and loss of heterozygosity (LOH) of 1p or 11q. In addition, in infants less than 2 months of age, mass effect due to hepatomegaly with resultant compartment syndrome, liver failure, or renal failure have also been associated with stage 4S neuroblastoma. These patients are observed with supportive care(for asymptomatic patients with favorable tumor biology), chemotherapy (symptomatic patients, those with unfavorable tumor biology, and infants less than 3 months), surgery (rarely, patients with hepatomegaly that compromises the kidney or other abdominal organs), radiation therapy (rarely, patients with symptoms related to hepatomegaly from metastatic disease).

Signs and Symptoms

The symptoms of relapsed neuroblastoma vary widely depending on the tumor's size, location, and whether the cancer has spread (metastasized). Most neuroblastoma tumors originate in the abdomen, particularly in the adrenal glands, but they can also develop in nerve tissue in the neck, chest, or pelvis. As the disease progresses, it may spread to other parts of the body, including the liver, lymph nodes, bones, and bone marrow, leading to a broad range of symptoms depending on the affected areas.

Common symptoms in specific affected areas:

Adrenal Glands and Stomach Area: 

Abdominal pain: any discomfort or painful sensation felt in the region between the chest and the groin.

Painless lump or mass: firm, non-tender subcutaneous nodules that can sometimes present with a bluish or purplish hue in infants that typically doesn’t cause discomfort or pain to the touch.

Diarrhea: a rare feature usually caused by a paraneoplastic syndrome called WDHA syndrome, linked to tumor secretion of vasoactive intestinal peptide (VIP), or as a side effect of surgical dissection near major abdominal blood vessels.

Constipation: infrequent or difficult bowel movements caused by a growing abdominal or pelvic tumor pressing on the intestines, or by nerve compression affecting bowel function

Chest and Neck Area:

Wheezing: a high-pitched whistling sound while breathing caused by a tumor pressing on or narrowing the airways.

Difficulty breathing: shortness of breath or labored breathing caused by a tumor compressing the lungs, airways, or surrounding structures in the chest.

Drooping eyelids (ptosis): a sagging of one or both upper eyelids caused by nerve damage or pressure from a tumor in the neck or upper chest.

Changes in pupil size: unequal pupil sizes (anisocoria) or an abnormally small pupil caused by disruption of the sympathetic nerves controlling the eye, often occurring as part of Horner syndrome.

Spine Area:

Back pain: discomfort or aching in the back caused by a tumor pressing on the spine, surrounding tissues, or nerves.

Trouble urinating or passing a bowel movement: difficulty emptying the bladder or bowels due to compression of the spinal cord or nerves that control bladder and bowel function.

Weakness in the legs: reduced strength, difficulty walking, or loss of coordination caused by pressure on the spinal cord or nearby nerves.

Metastatic Neuroblastoma:

Bone pain: aching or tenderness in the bones caused by the spread of cancer cells to the bone, which may cause young children to limp or refuse to walk.

Dark, bruise-like circles around the eyes (raccoon eyes): dark discoloration around the eyes caused by the spread of neuroblastoma to the bones surrounding the eye sockets.

Fever: an elevated body temperature resulting from the body's inflammatory response to cancer or, less commonly, infection.

Fussiness: unusual irritability or increased crying in infants and young children due to pain, discomfort, or illness caused by the tumor.

Painless lumps of tissue under the skin: firm, non-tender subcutaneous nodules caused by the spread of neuroblastoma cells beneath the skin that typically do not cause discomfort when touched.

Not growing or gaining weight as expected: poor growth or failure to gain weight due to the body's increased energy demands from cancer, decreased appetite, or disruption of normal metabolism.

Statistics on Relapsed Neuroblastoma 

Prevalence

Neuroblastoma is one of the more prevalent childhood cancers and is the most common in infants younger than a year old. The average age at diagnosis is between one and two years old. It is rarely detected through ultrasound before the child is born and is extremely rare in people over the age of ten. Among children with neuroblastoma, there is little to no gender bias, with neuroblastoma being a little more common in boys than girls, with a 1.3 to 1.2 ratio. 

Throughout the United States, there are around 600-800 new cases diagnosed each year. Overall, neuroblastoma represents 6-10% of all childhood cancer diagnoses and unfortunately represents 12-15% of pediatric cancer-related deaths. 

Demographics of Neuroblastoma

Table 1.  Demographic data from a group of specialists’ analysis on frequency, survival rates, and racial/ethnic differences of neuroblastoma among children. In this study, there were a total of 11,543 cases (2003-2019) from the USCS database. 

Sex	Number	Percentage
Male	6088	52.7%
Female	5455	47.3%
Age
Under 12 months old	3924	34%
1-4 years old	5761	49.9%
5-9 years old	1315	11.4%
10-14 years old	376	3%
15-19 years old	167	1.5%
Race/Ethnicity
White	7455	65%
Black	1476	12.8%
Hispanic	1836	15.9%
Asian or Pacific Islander	513	4.5%
American Indian or Alaska Native	90	0.7%
Unknown heritage	173	1.5%

The demographic data reveals that most neuroblastoma cases are male and are in children ages one to four. This table also shows that white children represented the largest proportion of patients; Hispanic patients and black patients made up most of the neuroblastoma cases. However, the percentages do not truly represent the disease risk among ethnic groups, it really represent the distribution among cases.

Survival Rates and Risk

Neuroblastoma accounts for 12%-15% of pediatric cancer-related deaths; however, some characteristics of the disease contribute to the survival rate. This is because neuroblastoma is one of the most aggressive cancers due to it being highly metastatic, which means it can spread to other parts of the body quickly. This also makes it easier for the cancer to develop resistance to the therapies, which is why 50-60% of high-risk neuroblastoma patients will have their disease relapse after initial treatment. When the neuroblastoma has spread throughout the body, the survival rate of the patient becomes less than 40% even with intense treatment. While patients without metastasis are very low risk, their survival rate is 82%-90%.

Limitations and Caution

Despite the promising impacts of ALK-targeted therapy, several limitations remain. Not all patients with neuroblastoma benefit from ALK inhibitors because only a subset of tumors contain ALK mutations or amplifications. Even in patients with ALK-positive neuroblastoma, each ALK mutant can respond differently to treatment. For example, certain mutations, such as F1174L, are inherently less sensitive to first-generation inhibitors like crizotinib, requiring more potent next-generation drugs. In addition, tumors often develop acquired resistance through secondary ALK mutations or by activating alternative signaling pathways, allowing cancer cells to continue growing despite treatment. Another challenge is that tumor heterogeneity—where different cancer cells within the same tumor may carry distinct genetic changes—makes it difficult for a single targeted therapy to eliminate all cancer cells. Researchers are addressing these limitations by developing newer ALK inhibitors, identifying biomarkers that better predict treatment response, and investigating combination therapies that simultaneously target multiple signaling pathways to delay or overcome resistance, hoping to provide longer-lasting and more effective treatment options for children with high-risk or relapsed neuroblastoma. 

Additionally, like many targeted cancer therapies, ALK inhibitors can cause adverse effects that may require dose adjustments, treatment interruption, or careful monitoring. Common side effects include gastrointestinal symptoms, liver abnormalities, fatigue, and, less commonly, more serious complications such as lung toxicity. Because these therapies are often given to children with high-risk or relapsed neuroblastoma, physicians must carefully balance their potential benefits with the risk of adverse effects while monitoring patients throughout treatment. Continued clinical trials are needed to better understand the long-term safety of ALK inhibitors in pediatric patients and to develop treatments that are both more effective and less toxic.

Affected Patients and Population (Impacts)

Neuroblastoma is most commonly diagnosed in children younger than five years of age and is rare in children older than ten. Relapsed neuroblastoma occurs most frequently in patients who were initially diagnosed with high-risk disease, particularly those older than 18 months at the time of diagnosis and those with widespread metastatic tumors. The global burden of neuroblastoma is disproportionately higher in regions with a low Socio-Demographic Index (SDI), including South Asia and sub-Saharan Africa, where incidence and mortality have increased significantly. These disparities are associated with limited access to healthcare, delayed diagnosis, and higher rates of poverty.

Neuroblastoma has significant physical, emotional, and psychological effects on both children and their families. Children diagnosed with neuroblastoma commonly experience feelings of fear, anxiety, depression, and uncertainty throughout treatment. Many become increasingly dependent on their parents and caregivers, often fearing separation or the loss of loved ones. Even after successful treatment, survivors may experience long-term or late effects, including delayed physical and cognitive development, behavioral and emotional challenges, learning difficulties, and psychological trauma resulting from their diagnosis and intensive treatment.

Families are also profoundly affected by a child's diagnosis. Parents often experience overwhelming stress, anxiety, guilt, and self-blame, questioning whether they could have recognized symptoms earlier or prevented the illness. Many struggle with uncertainty regarding treatment decisions and may lose confidence in the healthcare system, particularly when the diagnosis is delayed or the disease relapses. The emotional, financial, and caregiving demands of neuroblastoma can place considerable strain on family relationships and overall quality of life.

Approach and Targeted Therapy

Targeted therapy is given to patients who are classified as high-risk neuroblastoma. If ALK mutations are characterized through advanced genetic analysis, providers determine whether the patient is suited for targeted therapy. Patients with ALK-mutant status, high-risk, relapsed, adult-set, or hereditary neuroblastoma are qualified for an ALK-positive neuroblastoma treatment; they are given ALK inhibitor pills that are taken orally as pills or capsules, sometimes as a single agent or combined with standard chemotherapy. 

Through precision oncology, we are able to find more effective approaches for treating high-risk neuroblastoma and tailor each therapy to each patient. In ALK-positive neuroblastoma, ALK inhibitors like crizotinib, ceritinib, and brigatinib are used to treat high-risk neuroblastoma by targeting specific gene mutations to block tumor growth. By binding to the ALK protein, ALK inhibitors disrupt the signaling pathways responsible for cell proliferation and survival, ultimately inducing apoptosis (programmed cell death) and slowing or stopping tumor growth. In addition, these drugs may inhibit the formation of new blood vessels that supply the tumor, further limiting cancer progression. 

Although ALK inhibitors have significantly improved treatment options for patients with ALK-positive neuroblastoma, resistance to these therapies can develop over time. As a result, newer generations of ALK inhibitors have been developed to overcome resistance caused by additional mutations in the ALK gene.

Crizotinib was one of the first ALK inhibitors used to treat ALK-positive neuroblastoma and has demonstrated clinical effectiveness in reducing tumor growth. However, many tumors eventually develop resistance to crizotinib. 

Ceritinib is a second-generation ALK inhibitor that can be effective in some patients whose tumors have become resistant to crizotinib. 

Lorlatinib, a third-generation ALK inhibitor, has shown greater potency against a wide range of ALK mutations, including many that are resistant to earlier drugs. 

Another promising therapy, Repotrectinib (TPX-0005), is a next-generation tyrosine kinase inhibitor that targets ALK and related proteins. Early clinical studies suggest that it may be particularly effective when combined with chemotherapy. 

Alectinib (Alecensa) is another selective ALK inhibitor that has demonstrated activity against ALK-mutated neuroblastoma and provides an additional targeted treatment option for patients with this genetic alteration. A farnesyltransferase inhibitor (FTI) is an inhibitor that blocks an enzyme named farnesylation, preventing a specific chemical modification called farnesylation, which certain proteins like RAS need to bind to cell walls.

When neuroblastoma cells lose miR-1304-5p (a specific human microRNA that functions primarily as a tumor suppressor across several cancer types), they become less responsive to ALK inhibitors. For example, reduced levels of miR-1304-5p make neuroblastoma cells less sensitive to ALK inhibitors by allowing the NRAS/RAS-MAPK signaling pathway to remain active. To counter this resistance, researchers have paired ALK inhibitors with lonafarnib, a FTI that blocks RAS protein activity. By inhibiting both the ALK and RAS/MAPK pathways simultaneously, this combination increases apoptosis (programmed cell death) and reduces tumor growth more effectively than ALK inhibitors alone in preclinical studies.

Another approach combines lorlatinib with idasanutlin, a drug that activates the p53 tumor suppressor pathway. Lorlatinib continues to directly target the abnormal ALK protein, preventing the signaling that promotes neuroblastoma cell growth, while idasanutlin enhances the treatment by triggering apoptosis through p53 activation. Together, these drugs produce complete tumor regression and delayed tumor recurrence in preclinical models of ALK-amplified neuroblastoma.

These combination therapies demonstrate that ALK-targeted treatment can be strengthened by simultaneously blocking other pathways that cancer cells use to escape ALK inhibition. Although these strategies are still being investigated, they highlight how researchers are improving ALK-targeted therapies to overcome resistance and provide more effective, long-lasting treatment options for children with high-risk or relapsed neuroblastoma. 

Conclusion

Relapsed Neuroblastoma is a hard-hitting childhood cancer that not only carries a physical toll on the patient but also emotional burdens on every family. It’s important to raise awareness of this disease to help the affected patients and their families feel seen in their struggle and feel supported by their communities. Raising awareness also encourages breakthroughs in medicine for neuroblastoma, such as more research for improved treatment options and diagnosis. People can spread the message about neuroblastoma by attending or organizing events, like wearing a specific color within a big group or volunteering in a community. Another effective way is to fundraise. Fundraising sends a message while also providing financial help straight to the cause. Similarly, a good way to advocate is by supporting government policies that fund treatment and research for rare diseases. 

Unfortunately, high levels of awareness won’t solve all of the researchers’ problems right away. Many ALK-targeted therapies can cause even more side effects, making it even harder for the patients to truly heal because the physicians have to balance out the medications and treatments. Researchers still have so much to learn about how ALK signals through different pathways to really create effective and healthy treatments for pediatric neuroblastoma patients. But with efforts towards research, supportive communities, and advocacy,  patients with neuroblastoma and their families will be able to look toward a brighter future.  

References 

AlKhazal, Albatool, et al. “Emerging Clinical and Research Approaches in Targeted Therapies for High-Risk Neuroblastoma.” Frontiers in Oncology, vol. 15, 4 Mar. 2025, doi:10.3389/fonc.2025.1553511.

Bheemavarapu, Bhumika, et al. “Integration of ALK Gene Mutations and Targeted Therapies in Pediatric High-Risk Neuroblastoma: Advancements in Precision Oncology.” Annals of Medicine and Surgery, vol. 87, 11 Aug. 2025, pp. 6470–6479, doi:10.1097/MS9.0000000000003697.

Boston Children's Hospital. “Neuroblastoma.” Boston Children's Hospital, https://www.childrenshospital.org/conditions-treatments/neuroblastoma. Accessed July 2026.

Braungart, Sarah, and Paul D. Losty. “Diagnosis and Management of Neuroblastoma in Children.” World Journal of Pediatric Surgery, vol. 9, no. 1, 6 Jan. 2026, e001127, doi:10.1136/wjps-2025-001127.

Campbell, Kevin et al. “A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019.” Pediatric blood & cancer vol. 71,1 (2024): e30732. doi:10.1002/pbc.30732

Canadian Cancer Society. “Targeted Therapy for Neuroblastoma.” Canadian Cancer Society, 2020, https://cancer.ca/en/cancer-information/cancer-types/neuroblastoma/treatment/targeted-therapy. Accessed July 2026.

Claeyssens, Claire, et al. “An Unusual Case of Neuroblastoma Presenting with Prolonged Watery Diarrhea in a Pediatric Patient.” Biochemia Medica, vol. 35, no. 2, 2025, 020901, doi:10.11613/BM.2025.020901.

Cleveland Clinic. “Neuroblastoma: What Is It, Stages, Causes, Symptoms, Treatments.” Cleveland Clinic, 14 Dec. 2020, https://my.clevelandclinic.org/health/diseases/14390-neuroblastoma.

Davis, S et al. “The incidence and epidemiologic characteristics of neuroblastoma in the United States.” American journal of epidemiology vol. 126,6 (1987): 1063-74. doi:10.1093/oxfordjournals.aje.a114745

De Bona, Amina, et al. “Neuroblastoma in Childhood: Biological Insights, Risk Stratification, and Advances in Multimodal Therapy.” Journal of Clinical Medicine, vol. 15, no. 3, 30 Jan. 2026, p. 1101, doi:10.3390/jcm15031101.

Holla, Vijaykumar R., et al. “ALK: A Tyrosine Kinase Target for Cancer Therapy.” Cold Spring Harbor Molecular Case Studies, vol. 3, no. 1, 2017, a001115, doi:10.1101/mcs.a001115.

Hou, Helei, et al. “The Safety and Serious Adverse Events of Approved ALK Inhibitors in Malignancies: A Meta-Analysis.” Cancer Management and Research, vol. 11, 7 May 2019, pp. 4109–4118, doi:10.2147/CMAR.S190098.

Kawano, Asuka, et al. “Stage 4S Neuroblastoma: Molecular, Histologic, and Immunohistochemical Characteristics and Presence of 2 Distinct Patterns of MYCN Protein Overexpression—A Report From the Children's Oncology Group.” The American Journal of Surgical Pathology, vol. 45, no. 8, 2021, pp. 1075–1081, doi:10.1097/PAS.0000000000001647.

“Key Statistics for Neuroblastoma.” American Cancer Society, 2025, https://www.cancer.org/cancer/types/neuroblastoma/key-statistics.html. Accessed July 2026.

King, Donna Marie. “Rare Disease Day: Why Awareness Matters and How You Can Participate.” TGEN, 22 January 2024, https://www.tgen.org/blog/rare-disease-day-why-awareness-matters-and-how-you-can-participate/. Accessed July 2026.

Madhwacharya, Aravind, et al. “Review of the Targeted Therapy for Advanced/Aggressive Neuroblastoma as Adjuncts to Standard Therapy.” The European Society of Medicine, 31 July 2025, https://esmed.org/targeted-therapy-advances-in-high-risk-neuroblastoma/. Accessed July 2026.

Mayo Clinic. “Neuroblastoma.” Mayo Clinic, Mayo Foundation for Medical Education and Research, 26 Apr. 2024, https://www.mayoclinic.org/diseases-conditions/neuroblastoma/symptoms-causes/syc-20351017.

MedlinePlus Genetics. “ALK Gene.” MedlinePlus, U.S. National Library of Medicine, https://medlineplus.gov/genetics/gene/alk/.

National Cancer Institute. “Neuroblastoma Treatment (PDQ®)–Health Professional Version.” National Cancer Institute, U.S. Department of Health and Human Services, https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq.

“Neuroblastoma.” Nationwide Children's Hospital, https://www.nationwidechildrens.org/conditions/neuroblastoma. Accessed July 2026.

Neuroblastoma Canada. “Statistics.” Neuroblastoma Canada, https://www.neuroblastoma.ca/resources/statistics. Accessed July 2026.

Schonert, Jonathan, et al. “Neuroblastoma Masquerading as Constipation: Reducing Diagnostic Error With the Pediatric Abdominal Point-of-Care Ultrasound Survey.” Cureus, vol. 16, no. 11, 25 Nov. 2024, e74427, doi:10.7759/cureus.74427.

Vo, Kieuhoa T., et al. “Pattern and Predictors of Sites of Relapse in Neuroblastoma: A Report From the International Neuroblastoma Risk Group (INRG) Project.” Pediatric Blood & Cancer, vol. 69, no. 9, 2022, e29616, doi:10.1002/pbc.29616.